In the past several years, there has been much controversy surrounding the possible link between a class of Hepatitis C drugs known as direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC), or liver cancer. The DAA drugs include Harvoni, Sovaldi, Viekira Pak, Technivie, Olysio, Daklinza, Epclusa, and Zepatier. In July, I wrote an … [Read more...]
Can Hepatitis C Drugs Harvoni Or Sovaldi Cause Return Of Liver Cancer?
In April 2017 this news report, “The Link Between Direct-Acting Antiviral Therapy for Hepatitis C Virus and Liver Cancer Risk Continues To Be Debated”, was published on the PracticeUpdate website. This recent report draws upon eight new medical studies which were presented at the International Liver Congress 2017, from April 19 to 23, 2017, in … [Read more...]
Safety of Hepatitis C Treatment Drugs Called Into Question
UPDATE: On February 14, 2017, the FDA released a Black Box warning for these drugs with the following text:Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death.(2/16/17).Recently, the safety of the newer hepatitis C treatment drugs -- such as Solvadi and Harvoni -- is … [Read more...]
Black-Box Warning For Harvoni, Sovaldi, Viekira Pak: Hepatitis B Risk
Direct-acting antivirals (DAAs) are a class of prescription medicines that are FDA-approved to treat adults with hepatitis C virus (HCV) infection. These medicines are available as single-ingredient products and also in combination with other HCV medicines. Here is a list of direct-acting antivirals currently available in the US: Daklinza … [Read more...]